Press Releases

Printer Friendly Version View printer-friendly version
<< Back
Implant Sciences Signs Cooperative Research & Development Agreement With TSL S&T, a Directorate of the U.S. Department of Homeland Security
Quantum Sniffer(TM) QS-B220 Explosives and Narcotics Trace Detector Selected for TSL Technology Optimization Partnership

WILMINGTON, MA, Nov 02, 2011 (MARKETWIRE via COMTEX) --

Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced that its Quantum Sniffer(TM) QS-B220 benchtop explosives trace detector has been approved to partner with the developmental test and evaluation group of the Transportation Security Laboratory (TSL) in order to optimize the QS-B220 detection technology. TSL is a Department of Homeland Security Federal Laboratory within the DHS Science and Technology Directorate (S&T), located at the William J. Hughes Technical Center, Atlantic City International Airport, New Jersey.

Implant Sciences has signed a Cooperative Research and Development Agreement (CRADA) with DHS S&T TSL to officially begin its technology optimization.

DHS S&T/TSL's core mission is to enhance homeland security, including the research, development and validation of solutions to detect and mitigate the threat of improvised explosive devices (IEDs). DHS S&T establishes CRADAs as public-private partnerships designed to expeditiously mature and deploy security technologies and to prepare products to achieve Transportation Security Administration (TSA) certification/qualification. TSA certified products may be used at ports of entry across the U.S., including airports.

Implant Sciences' Vice President of Technology, Todd Silvestri stated, "The insight of the professionals at TSL will be invaluable in preparing the QS-B220 to meet TSA's expectations. TSL brings extensive experience and expertise to the table which will help us build a better product."

"We are proud to be able to work with S&T to optimize our technology. This is a great example of a private-public partnership that helps save money for taxpayers while improving security in the United States," concluded Implant Sciences' President and CEO, Glenn D. Bolduc.

About the Quantum Sniffer QS-B220

The QS-B220 Quantum Sniffer, introduced in May 2011, is a benchtop explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, or homemade explosives and narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability. The QS-B220 benchtop explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act).

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. The QS-H150 and QS-B220 are Department of Homeland Security (DHS) Qualified Anti-Terrorism Technologies under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by U.S. or foreign governments or by other law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences Corporation

Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor Contact:
Laurel Moody
646-810-0608
Email Contact


SOURCE: Implant Sciences

http://www2.marketwire.com/mw/emailprcntct?id=F9E0320EE00AEEAD
http://www2.marketwire.com/mw/emailprcntct?id=BE60486161993F19